Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis
Tolebrutinib was not superior to teriflunomide in decreasing annualized relapse rates among participants with relapsing multiple sclerosis. (Funded by Sanofi; GEMINI 1 and GEMINI 2 ClinicalTrials.gov numbers, NCT04410978 and NCT04410991, respectively.).
Authors
- Patrick Benoit (ORCID: https://orcid.org/0000-0002-5983-622X)
- Jiwon Oh (ORCID: https://orcid.org/0000-0001-5519-6088)
- Carolina Ionete (ORCID: https://orcid.org/0000-0002-0147-5441)
- Bruce Cree (ORCID: https://orcid.org/0000-0001-7689-2533)
- Erik Wallstroem
- Heinz Wiendl (ORCID: https://orcid.org/0000-0003-4310-3432)
- Christina R. Maxwell (ORCID: https://orcid.org/0000-0003-3425-9814)
- Maria Pia Sormani (ORCID: https://orcid.org/0000-0001-6892-104X)
- Douglas Lorne Arnold (ORCID: https://orcid.org/0000-0003-4266-0106)
- Timothy J. Turner (ORCID: https://orcid.org/0000-0001-9770-2647)
- Yixin Chen (ORCID: https://orcid.org/0000-0001-7701-4687)
- Ho-Jin Kim (ORCID: https://orcid.org/0000-0003-4489-9516)
- Sana Syed
Institutions
- The University of Sydney (AU)
- St. Michael's Hospital (CA)
- University of Freiburg (DE)
- University of Massachusetts Chan Medical School (US)
- University of California, San Francisco (US)
- University of Toronto (CA)
- Sanofi (France) (FR)
- Sanofi (United States) (US)
- National Cancer Center (KR)
- NeuroRx Research (Canada) (CA)
- Ospedale Policlinico San Martino (IT)
- McGill University (CA)
- University of Genoa (IT)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1056/nejmoa2415985
- Citations
- 36
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 52.98
Funders
- Sanofi